Critical agreement aims to accelerate access to important antibiotics
Webinar – Antibiotic shortages: causes, consequences, and solutions
The first novel antibiotic treatment in GARDP’s clinical development portfolio on track for potential FDA approval
Protecting the #PowerOfAntibiotics
The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant infections. Together with private, public and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.
Critical agreement paves way for new model to accelerate access to important antibiotics for serious bacterial infections
G20 Health Ministers highlight urgent need to develop new antimicrobials to tackle resistance
Antibiotic resistance can affect anyone, anywhere
Antibiotic resistance occurs when bacteria change over time and no longer respond to treatment. Millions of people suffer due to antibiotic resistance every year, and nearly 1.3 million people die.
Raising our voices to protect the #PowerOfAntibiotics
A global crisis of antibiotic resistance
Antibiotic resistance has been identified as one of the top 10 global health threats by the World Health Organization.
Antibiotic resistance is spreading all over the world as a pandemic of drug-resistant infections.
Low- and middle-income countries, and certain population groups like children and the elderly, are hit hardest.
If left unchecked, antibiotic resistance may make it too risky to carry out routine surgeries and other modern medical interventions.
GARDP is acting now to counter drug resistance and save lives
GARDP’s “5 by 25” initiative aims to deliver five new treatments by 2025 for bacterial infections that pose the greatest threat to human health.
GARDP’s agreements with pharmaceutical and biotech companies have the potential to slash delays in access to antibiotics from decades to years.
GARDP works with governments, the pharmaceutical and biotech industry, academia, and members from civil society around the world.
Addressing urgent threats to public health
1 in 5 deaths caused by drug-resistant infections occur in children under the age of five, and up to 3 million newborns get serious infections that lead to sepsis every year.
Serious Bacterial Infections
Serious bacterial infections are among the major causes of death for people in hospitals and other healthcare settings.
Sexually Transmitted Infections
Gonorrhoea affects 82 million people each year, and disproportionately harms women. Resistant strains are spreading around the world.
Discovery & Exploratory Research
Growing drug resistance is outpacing the development of antibiotics for the most difficult-to-treat infections. Producing such antibiotics starts with the earliest stage of drug development.
Access to Antibiotics
Lack of access to novel antibiotics is a global problem that acutely affects whole countries and regions as well as certain population groups like children.